Count What Matters: Advanced Metrics to Value a Pharma Patent Portfolio Before the Generic Cliff
The Problem With Citation Counts A patent that has been cited 400 times sounds impressive. An IP manager can drop […]
After the Patent: Big Pharma’s Branded Generic Playbook
The Problem Nobody Admits Out Loud Every large pharmaceutical company has the same conversation at some point. A blockbuster drug
After the Patent: Big Pharma’s Branded Generic Playbook Read Post »
30 Months vs. 9 Months: How the US and China Patent Linkage Gap Reshapes Global Drug Competition
A comparative analysis of the statutory stay periods that define when generic and biosimilar manufacturers can enter the world’s two
Stop the Clock: How Divisional Patents Block Cheaper Meds in Europe
The most effective weapon in the European pharmaceutical patent arsenal is not the primary compound patent. It is the administrative
Stop the Clock: How Divisional Patents Block Cheaper Meds in Europe Read Post »
Why Complex Generics Command Premium Economics: How to Win the Complex Generics Race Before It Starts
Strategic and Regulatory Pathways for Launching High-Value Complex Generics The standard generic drug business is a race to the bottom.
Get Your ANDA Approved: The Generic Manufacturer’s Complete Checklist for Timely FDA Approval
A practical guide for regulatory affairs teams, IP counsel, and C-suite decision-makers The Stakes of the First Submission Every year,
Read the Orange Book, Then Ignore It: How Smart Supply Chains Use Patent Intelligence
The Gap Between Patent Data and Supply Chain Decisions Every procurement director at a hospital system, every formulary manager at
Read the Orange Book, Then Ignore It: How Smart Supply Chains Use Patent Intelligence Read Post »
Pick the Right Pathway: How 505(b)(2) Beats the Branded Generic Every Time — Unless It Doesn’t
The Decision That Determines Your Revenue Ceiling Somewhere between completing a Phase II study and walking into an FDA pre-NDA
The Generic Price Drop: Exact Benchmarks for What Happens to Drug Costs in the First Year
The Moment the Monopoly Ends On November 30, 2011, Lipitor lost its U.S. patent protection. Within 90 days, the price
